Literature DB >> 24088108

Eculizumab in atypical hemolytic-uremic syndrome.

Andreas D Kistler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24088108     DOI： 10.1056/NEJMc1308826

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Quantification of the IgG2/4 kappa Monoclonal Therapeutic Eculizumab from Serum Using Isotype Specific Affinity Purification and Microflow LC-ESI-Q-TOF Mass Spectrometry.

Authors:  Paula M Ladwig; David R Barnidge; Maria A V Willrich
Journal:  J Am Soc Mass Spectrom       Date:  2016-12-21       Impact factor: 3.109

Review 2.  Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.

Authors:  Maurizio Salvadori; Giuseppina Rosso; Elisabetta Bertoni
Journal:  World J Nephrol       Date:  2015-05-06

3.  ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.

Authors:  Chong H Kim; Sierra C Simmons; Lance A Williams; Elizabeth M Staley; X Long Zheng; Huy P Pham
Journal:  Transfusion       Date:  2017-06-23       Impact factor: 3.157
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.